OVERCOMING BIOLOGICAL BARRIERS TO DRUG DELIVERY
The Mitchell Lab is based in the Department of Bioengineering at the University of Pennsylvania. Our research lies at the interface of biomaterials science, drug delivery, and cellular and molecular bioengineering to fundamentally understand and therapeutically target biological barriers. We apply our research findings and the technologies developed to a range of human health applications, including cancer metastasis, immunotherapy, genome editing, cardiovascular disease, and regenerative medicine. Current research projects include: synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acids (siRNA, miRNA, mRNA, CRISPR-Cas9) for cancer therapy; engineering of immune cells for immunotherapy and vaccines; investigating the influence of biomaterial chemical structure on in vivo transport to target cells and tissues using high-throughput screening platforms; and novel drug delivery technologies for tissue engineering and regenerative medicine.
March 2019 – Mike is a recipient of the 2019 Controlled Release Society T. Nagai Award, which he will receive at the Controlled Release Society Annual Meeting in Valencia, Spain in July 2019. The award is featured by Penn Engineering.
March 2019 – Rachel’s paper on delivery technologies for cancer immunotherapy in collaboration with Carl June’s Lab (Penn Medicine) is published in Nature Reviews Drug Discovery and is featured on the journal cover.
October 2018 – Mike is a recipient of the 2018 NIH Director’s New Innovator Award. The 5-year, $2.4M award will support our lab’s research on engineering non-viral gene delivery systems that target the bone marrow microenvironment to treat chemoresistant cancers. The award is featured by several news outlets, including the NIH, Penn Today, and Penn Engineering.